Form 4: Vaxcyte Director Teri Loxam Acquires Shares

Vaxcyte, Inc. reports that Director Teri Loxam acquired shares and stock options on June 15, 2026.

Summary

• Director Teri Loxam acquired 2,265 shares of common stock and 11,389 stock options on June 15, 2026.
• The common stock acquisition was valued at $0, indicating it was likely a grant or award.
• The stock options have an exercise price of $49.56 and an expiration date of June 15, 2036.
• The restricted stock units (RSUs) underlying the common stock will vest on June 15, 2027, or the day before the next annual meeting, subject to continuous service.
• Delivery of vested RSUs can be deferred until separation from service or a change in control, as per the Nonqualified RSU Deferral Program for Non-Employee Directors.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as director stock acquisitions can signal confidence, but the nature of the acquisition (award) and the exercise price of options are key factors to monitor.

Positives

• Director acquisition of shares and options can signal confidence in the company's future prospects.
• The acquisition of a significant number of stock options suggests potential for future value creation for the director.
• The vesting schedule for RSUs and options provides a retention incentive for the director.

Negatives

• The acquisition of common stock at a $0 price suggests it was an award rather than an open market purchase, which may not reflect a direct investment of personal capital.
• The exercise price of the stock options ($49.56) is a key level for future profitability on those options.

Risks

• The vesting of RSUs and stock options is contingent on the Reporting Person's continuous service, meaning departure from the company before vesting would result in forfeiture.
• The value of the stock options is subject to market fluctuations and the company's stock performance.

Future Outlook

The vesting schedules for RSUs and stock options indicate a forward-looking incentive structure tied to continued service and potential future stock performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are closely watched by the market as potential indicators of management's view on the company's valuation and future prospects within the biotechnology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret director's acquisition as a positive signal of confidence, potentially influencing investment decisions.
• Employees: The retention incentives tied to vesting schedules may indirectly reflect company culture and long-term planning.
• Management: The deferral program offers flexibility in compensation management.

Next Steps

• Monitoring the vesting of RSUs and stock options.
• Observing the company's stock performance relative to the option exercise price.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, Securities, SEC Filing